Type
. Linkage analysis of susceptibility to leprosy type using an IBD regression method. Genes and immunity [Internet]. 2004;5(3):221-5. Available from: http://www.nature.com/gene/journal/v5/n3/pdf/6364062a.pdf
Type
. Leprosy control strategies and the integration of health services: an international perspective. Cadernos de saude publica [Internet]. 2003;19(6):1567-81. Available from: http://www.scielosp.org/pdf/csp/v19n6/a02v19n6.pdf
Type
. Leprosy: dental and periodontal status of the anterior maxilla in 76 patients. Oral diseases. 2004;10(1):19-21.
Type
. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. The American journal of tropical medicine and hygiene. 2004;70(2):197-200.
Type
. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. The Journal of clinical investigation. 2004;113(5):701-8.
Type
. [Health service organization during the age of pestilence. 2]. Le infezioni in medicina. 2003;11(4):216-21.
Type
. Leprosy in children: association between clinical and pathological aspects. Journal of tropical pediatrics. 2004;50(1):12-5.
Type
. Japanese leprosy patients continue to fight social stigma. 2 years after landmark court ruling, incarcerated patients are still fearful of returning home. Lancet (London, England). 2004;363(9408):544.
Type
. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cel. International immunopharmacology. 2004;4(1):1-14.
Type
. [Generalized adenopathy as a manifestation of type 2 reactional leprosy]. Biomedica : revista del Instituto Nacional de Salud. 2003;23(4):373-87.